Breaking WORLD PHARMA NEWS

Innovative ‘poop pills’ show promising results in clinical trials for multiple types of cancer

Fecal microbiota transplants (FMT), can dramatically improve cancer treatment, suggest two groundbreaking studies published in the prestigious Nature Medicine journal. The first study shows that the toxic side effects of drugs to treat kidney cancer could be eliminated with FMT. The second study suggests FMT is effective in improving the response to immunotherapy in patients with lung cancer and melanoma.

Read more …

Sanofi announces the signing of a share buyback mandate for up to €1 billion

On January 29, 2026, Sanofi announced its intention to execute a share buyback program in 2026 of €1 billion.

On February 2, 2026, Sanofi entered a mandate with an investment service provider for this program. Under the terms of the mandate, Sanofi will repurchase its own shares for a total consideration of up to €1 billion, between February 3, 2026, and December 31, 2026, at the latest(1).

Read more …

How a heart medication could unlock a new targeted approach in lymphoma

A team of researchers at VCU Massey Comprehensive Cancer Center discovered an innovative way to use a drug already approved in treating irregular heartbeat to selectively target specific functions of enzymes in lymphoma, effectively killing cancer cells and reducing tumor growth with little to no toxicity. Recent findings published in Pharmacological Research set the groundwork for how this strategy could help transform the future of precision medicine in cancer.

Read more …

A broken DNA repair tool accelerates aging

Although DNA is tightly packed and protected within the cell nucleus, it is constantly threatened by damage from normal metabolic processes or external stressors such as radiation or chemical substances. To counteract this, cells rely on an elaborate network of repair mechanisms. When these systems fail, DNA damage can accumulate, impair cellular function, and contribute to cancer, aging, and degenerative diseases.

Read more …

AstraZeneca begins trading on the New York Stock Exchange

AstraZeneca today begins trading its ordinary shares on the New York Stock Exchange (NYSE) for the first time, enabling more US investors to participate in the Company’s strong growth. With this change the trading of AstraZeneca ordinary shares is now aligned across the NYSE, the London Stock Exchange (LSE) and Nasdaq Stockholm (STO) under a harmonised listing structure.

Read more …

Metformin shown to prevent Long COVID across risk groups in multiple randomized trials

Multiple randomized clinical trials and electronic health record studies now show that metformin, a widely used and well-established medication, significantly reduces the risk of developing Long COVID when taken during or shortly after acute infection with SARS-CoV-2. The findings were published in Clinical Infectious Diseases.

In the paper, the University of Minnesota Medical School research team provides information about metformin and summarizes several studies in low, standard and high risk populations

Read more …

Two days of oatmeal reduce cholesterol level

A short-term oat-based diet appears to be surprisingly effective at reducing the cholesterol level. This is indicated by a trial by the University of Bonn, which has been published in the journal Nature Communications. The participants suffered from a metabolic syndrome - a combination of high body weight, high blood pressure, and elevated blood glucose and blood lipid levels. They consumed a calorie-reduced diet, consisting almost exclusively of oatmeal, for two days.

Read more …

Chemotherapy rewires gut bacteria to curb metastasis

Chemotherapy commonly damages the intestinal lining, a well-known side effect. But this injury does not remain confined to the gut. It reshapes nutrient availability for intestinal bacteria, forcing the microbiota to adapt.

The researchers report that chemotherapy-induced damage to the intestinal lining alters nutrient availability for gut bacteria, reshaping the microbiota and increasing the production of

Read more …

Abbott increases quarterly dividend for 54th consecutive year

Abbott (NYSE: ABT) announced that its board of directors has increased the company's quarterly common dividend to 63 cents per share, an increase of 6.8%. The company's quarterly dividend payout has increased more than 70% since 2020.

This marks Abbott's 54th consecutive year of dividend growth and is the 408th consecutive quarterly dividend to be paid by Abbott since 1924.

Read more …

New nanoparticle technology offers hope for hard-to-treat diseases

A newly published perspective article in Nature Nanotechnology details groundbreaking nanoparticle technology to eliminate harmful, disease-causing proteins in the body. The technology marks a transformative leap in the potential to drug "undruggable" proteins, to treat diseases such as dementia and brain cancer.

The research was led by Chair Professor in Nanomedicine Bingyang Shi from the University of Technology Sydney (UTS), together with international collaborators Professor Kam Leong from Columbia University, and Professor Meng Zheng from Henan University.

Read more …